NCT01548157

Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule

A Randomized, Open Label, Single Dose, 2X2 Cross-over Study to Compare Pharmacokinetics Between Rosuvastatin 10mg and Omega-3 1g Co-administration and HCP1007 in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HCP1007 capsules and Rosuvastatin plus Omega-3.

Detailed description

The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HCP1007 capsules and Rosuvastatin plus Omega-3.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HCP1007 / omarco and crestor	HCP1007 / Rosuvastatin plus Omega-3

Timeline

• Start date: 2012-03-01
• Primary completion: 2012-03-01
• Completion: 2012-12-01
• First posted: 2012-03-08
• Last updated: 2013-06-04

Locations

1 site across 1 country: South Korea